Treatment of advanced lung cancer is one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and has an extremely poor prognosis. Thus, new therapeutic approaches are needed. Lung tumor formation depends on angiogenesis in which the vascular endothelial growth factor (VEGF) produced by cancer cells plays a pivotal role. Neutralizing VEGF with a soluble VEGF receptor suppresses tumor growth; however, the anticancer effect with this therapy is weakened after the intratumoral vascular network is completed. In this study, we turned the expression of VEGF by tumors to therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 is controlled by the human VEGF promoter. This virus achieved good levels of viral replication in lung cancer cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with tropism modification of the virus to express the knob domain of Ad3, which improved infectivity for cancer cells. These VEGF promoter-based CRAds also showed a significant cell killing effect for various types of cancer lines other than lung cancer. Conversely, the VEGF promoter has low activity in normal tissues, and the CRAd caused no damage to normal bronchial epithelial cells. Since tumor-associated angiogenesis via VEGF signalling is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that VEGF promoter-based CRAds have the potential to be an effective strategy for cancer treatment.
Introduction
Lung cancer, one of the most common malignant tumors in the world, is the leading cause of cancer deaths in many countries. 1 Surgical resection remains the standard of care of patients with early-stage disease. Unfortunately, over 70% of all patients with non-small cell lung cancer (NSCLC) have inoperable disease at the time of diagnosis. Despite the use of optimal chemotherapy and radiotherapy regimens, the outcome of patients with advanced disease is extremely poor, and little progress has occurred in the last decade. This points to a need for developing more effective treatments.
Antiangiogenesis approaches to therapy are promising treatment alternatives, since several studies have shown that angiogenesis is one of the important factors in the growth, progression and metastasis of solid tumors. 2, 3 Among the many known angiogenic factors, such as basic fibroblast growth factor, angiogenin, interleukin-8, platelet-derived endothelial cell growth factor and vascular endothelial growth factor (VEGF), VEGF is now believed to play a pivotal role in tumor-associated angiogenesis in lung cancer as well as other solid tumors. In fact, several papers have reported that the resected lung cancer tissue express the VEGF mRNA and protein abundantly based on immunohistochemical and reverse transcription-polymerase chain reaction (RT-PCR) analysis. 4, 5 Moreover, the high expression levels of VEGF mRNA and protein are correlated with poor prognosis in lung cancer patients, 4, 5 indicating that advanced lung cancer tissues tend to express VEGF. We also reported the negative correlation between VEGF expression and dendritic cell infiltration in the tumor, suggesting an immunosuppressive function of VEGF, which may promote the tumor growth. 6 These clinical findings show that VEGF is a possible target molecule for new lung cancer treatments.
In fact, we reported that soluble VEGF receptor gene transfer was able to neutralize the angiogenic effect of VEGF and suppress tumorigenesis in vivo. 7, 8 However, the effect of anti-VEGF treatment is diminished in the well-established tumors that already have a developed blood vessel network. Nevertheless, the fact that established tumors still express higher levels of VEGF than normal tissues suggested that there might still be a way to exploit this differential for therapeutic advantage.
An emerging strategy for cancer therapy is the use of conditionally replicative adenoviruses (CRAds) that are designed to exploit key differences between tumor cells and normal cells to allow viral replication only in the former. Two basic strategies have been used to generate CRAds. 9 A type I approach, such as Ad-dl1520 (ONYX-015) or AdD24, involves directly mutating a key Ad gene such as E1 to take advantage of the disordered cell cycle regulation in tumor cells with, for example, functionally deficient p53 or RB signalling. 10, 11 The type II approach involves replacement of wild-type Ad promoters with tumor-specific promoters to drive the expression of genes essential for Ad replication, including E1. The promoters of alpha-fetoprotein, 12 prostate specific antigen, 13 osteocalcin 14 and MUC1 15 have already been used to generate type II CRAds to treat hepatocellular carcinoma, prostate cancer and breast cancer, respectively. We also reported that the midkine promoter and tyrosinase promoter based CRAds are useful for the treatment of pediatric solid tumors and melanoma, respectively. 16, 17 ONYX-015 and CV706 (PSA promoter-based) have already been used and shown to be safe in clinical trials. 18, 19 Based on these findings, we utilized the VEGF promoter, which is activated in advanced lung cancer to generate a type II CRAd, to achieve selective replication and oncolysis in VEGF positive tumors. To test our hypothesis, we replaced the native E1A promoter with the human 2.6 kb VEGF promoter and evaluated the oncolytic effect in various cell lines and in vivo. Furthermore, in view of the increasing evidence that levels of the coxsackie and adenoviral receptor (CAR) are low on many tumor types, we also generated a tropismmodified virus containing the receptor binding knob domain of Ad serotype 3 in place of the Ad5 knob. The NCI-H82, NCI-H460, NCI-H157, NCI-H322, NCI-H522, NCI-H1299, NCI-H358, NCI-N417, A427, A549 , lung cancer cell lines, BEAS-2B, normal human bronchial epithelial cell line, Panc-I, pancreas cancer cell line and HEK293 adenoviral transformed human embryonic kidney cell line were obtained from ATCC (American Type Culture Collection, Manassas, VA). QG56 and QG90 were provided by National Kyushu Cancer Center, Fukuoka, Japan). Human ovarian adenocarcinoma cell line SKOV3.ip1 was obtained from Dr Janet Price (MD Anderson Cancer Center, Houston, TX). The MeWo cell line was a gift of Dr Ian R Hart (St Thomas Hospital, London, UK). Cells were cultured in the media recommended by each provider and incubated at 371C and 5% CO 2 .
Materials and methods

Cell culture
Adenovirus vectors
The recombinant adenoviral vectors that express firefly luciferase were constructed through homologous recombination in Esherichia coli using the AdEasy system. 20 The 2.6 kb human VEGF promoter region derived from pVEGF-kpnI (provided from Dr Semenza at the Johns Hopkins University, Baltimore, MD) 21 was placed in front of the firefly luciferase gene in an Ad E1 shuttle vector, recombined with the E1-and E3-deleted adenoviral backbone vector pAdEasy 1, then transfected into 293 cells by standard techniques to form Ad5VEGFLuc. The luciferase gene and simian virus 40 polyadenylation signal were derived from pGL3 Basic (Promega, Madison, WI). As a control, a vector that containing the ubiquitously active cytomegalovirus (CMV) immediate early promoter (derived from plasmid pCEP4; Invitrogen, Carlsbad, CA) instead of the VEGF promoter was also constructed and named Ad5CMVLuc. The replication competent adenovirus (Ad), Ad5VEGFE1, was also generated from the same E1-and E3-deleted adenoviral backbone vector. Briefly, the fragment corresponding 489-3533 bp from the left end of the type 5 adenoviral genome was amplified by PCR and inserted in the E1 deleted region of the backbone vector. This fragment contains the transcriptional start site of the E1A gene but not the native E1A promoter. The 2.6 kb VEGF promoter region was placed upstream of this fragment. A control vector was also constructed in which the CMV promoter was placed in the same position upstream of E1A. The strategy for these three constructs is summarized in Figure 1 . Fiber modified CRAd, Ad5/3VEGFE1 was generated in similar manner as Ad5VEGFE1, but using Ad5/3E1-E3-deleted backbone vector derived from Ad5/ Figure 1 Schematic diagram of vector construction. These vectors are constructed from an E3 region-deleted Ad5 backbone and do not contain the Ad E1A promoter region (from nucleotide 324 to 488 of the Ad genome). Deletion of the E3 region was necessary, because of the 2.6 kb VEGF promoter we chose was too long to insert into the Ad genome without deletion of adenoviral E3 region. AdCMVE1 and AdVEGFE1 differ in the promoter driving E1A expression. We also used wild-type Ad5 (Ad5wt) as a control.
VEGF promoter-based replicative adenovirus K Takayama et al 3luc1 containing Ad3 knob in place of Ad5 wild-type knob gene as described previously. 22 To compare the difference in infectivity between the Ad5 and Ad5/3 chimeric vectors on our target cells, an Ad vector (Ad5/ 3luc1) that contains a CMV driven luciferase gene in E1 was compared to AdCMVLuc. Wild-type p53 protein expressing Ad, Ad5p53, which contains CMV driven p53 cDNA, was provided from Dr Ueno (University of Occupational and Environmental Health, Kitakyusyu, Japan) 23 The viruses were propagated in the Ad packaging cell line, 293HEK, and purified by double cesium chloride density gradient centrifugation, followed by dialysis against phosphate-buffered saline with 10% glycerol. The viral particle (VP) concentration was determined spectrophotometrically, using a conversion factor of 1.1 Â 10 12 VPs per absorbance unit at 260 nm, 24 and standard plaque assays on 293 cells were performed to determine infectious particles. 25 Analysis of VEGF RNA expression The VEGF RNA status of cell lines was analyzed by RT-PCR as described previously. 4 Total cellular RNA was extracted from 1 Â 10 7 cells using the RNeasy kit (Qiagen, Valencia, CA) and analyzed for VEGF and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) RNA with the GeneAmp RNA PCR core kit (Applied Biosystems), as described by the manufacturer. Briefly, 500 ng of total RNA was reverse-transcribed with the random hexamer and murine leukemia virus reverse transcriptase (501C 30 min) and amplified by PCR with 50 nM of primer pairs described below using a cycling program (initial step of 951C for 15 min, 27 cycles of 951C for 1 min and 601C for 1 min and 721C for 1 min, final step of 721C for 10 min). The primers used for the analyses were as follows; VEGF sense (5
. The intensity of RT-PCR band corresponding to VEGF121 and VEGF165 isoform was quantified using image analyzer, NIH image.
Measurement of VEGF protein in culture media
The VEGF protein expression was evaluated as described previously. 8 Briefly, 1 Â 10 5 cancer cells were cultured for 24 h in the serum-free media, and then the medium was collected. After centrifugation, the supernatant was stored at À801C until the assay. The VEGF protein in the culture medium was determined using an ELISA kit (Quantikine Human VEGF Immunoassay, R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. Each of the values given here is the mean of triplicate determination with respect to standardized cell numbers, 1 Â 10 5 cells.
In vitro analysis of VEGF promoter activation
The activity of the VEGF promoter in an adenovirus context was analyzed by infection of cells with luciferase expression vectors as reported previously. 16 Briefly, cells were plated in 12-well plates in triplicate at the density of 1 Â 10 5 cells/well. The next day, the cells were infected with Ad5VEGFLuc or Ad5CMVLuc at the multiplicity of infection (MOI) of 10 plaque-forming unit (PFU)/cell in Dulbecco's modified Eagle's medium with 2% fetal calf serum (FCS) for 3 h and then maintained in complete medium. The infected cells were harvested and treated with 100 ml of lysis buffer (Promega, cat no. E153A) after 2 days culture. A luciferase assay (Luciferase Assay System; Promega) and an FB12 luminometer (Zyluc Corporation, Oak Ridge, TN) were used for the evaluation of luciferase activities of Ad-infected cells. Luciferase activities were normalized by the protein concentration in cell lysate (Bio-Rad DC Protein Assay kit).
In vivo analysis of VEGF promoter activation For determination of luciferase gene expression in mouse organs, nude mice (Charles Rivers) received 1 Â 10 9 PFU of Ad5CMVluc or Ad5VEGFLuc by tail vein injection as reported previously. 16 After 2 days, mice were killed, and livers, kidneys, lungs and spleens were resected to measure the luciferase gene expression. The resected organs were placed in the polypropylene tubes, and immediately frozen in ethanol/dry ice. Frozen tissues ground to a fine powder was lysed using a tissue lysis buffer (Promega), and then luciferase activity was determined using a luciferase assay kit (Promega). The luciferase activity was normalized by protein concentration in the tissue lysate. Tumors were induced by injection of 1 Â 10 7 H157 cells on nude mice subcutaneously (Charles Rivers). When tumor formation was confirmed (6-8 mm in diameter), Ad5VEGFLuc (1 Â 10 8 PFU) or Ad5CMVLuc (1 Â 10 8 PFU) were injected into the tumor. Measurement of luciferase activity in tumor was performed in same fashion with other organs described above.
Analysis of viral genome amplification Viral DNA amplification was assessed as reported previously. 16 Cells were plated in a 12-well culture plate in triplicate at the density of 1 Â 10 5 cells/well. After overnight culture, cells were infected with replicationcompetent Ads (Ad5VEGFE1, Ad5CMVE1 or Ad5wt) or non-replicative Ad (Ad5CMVLuc) at the MOI of 10 for 3 h and then cultured for 24 h. The harvest of infected cells was followed by viral DNA isolation using Blood DNA kit (Qiagen, Valencia, CA). Viral DNA was eluted with 100 ml of elution buffer (10 mM Tris-Cl (pH 8.5)). Eluted samples (1 ml) were analyzed by real-time PCR analysis to evaluate Adenoviral E4 copy number using a LightCycler (Roche). Oligonucleotides corresponding to the sense strand of Ad E4 region (5 0 -TGACACGCATACTCG GAGCTA-3 0 : 34885-34905 nt), the antisense strand of E4 region (5 0 -TTTGAGCAGCACCTTGCATT-3 0 : 34977-34958 nt), and a probe (5 0 -CGCCGCCCATGCAACAA GCTT-3 0 : 34930-34951 nt) were synthesized, used as primers and probe for real-time PCR analysis. The PCR conditions were as follows: 35 cycles of denaturation (941C, 20 s), annealing (551C, 20 s), and extension (721C, 30 s). Adenovirus backbone vector pTG3602 (Transgene, Strasbourg, France) 26 was available for making a VEGF promoter-based replicative adenovirus K Takayama et al standard curve for Ad E4 DNA copy number. E4 copy numbers were normalized by the b-actin DNA copy number.
In vitro cytotoxicity assay For determination of virus-mediated cytotoxicity, 5 Â 10 3 cells were plated in 96-well plates in triplicate. After overnight culture, cells were infected with each Ads at various MOI for 3 h. The infection medium was then replaced with RPMI1640 containing 10% FCS. Viable cells using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt) assay (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay; Promega) were evaluated every 3 days. The MTS color development was quantified as optical density at 490 nm by an EL 800 Universal Microplate Reader (Biotec Instruments Inc.). To visualize the cytotoxic effect, crystal violet staining was also performed. 2 Â 10 5 cells were plated in 12-well plates and infected with each Ad at various MOI for 3 h. The infection medium was replaced with growth medium the next day. When cell lysis was observed, cells were fixed and stained with 1% crystal violet in 70% ethanol for 45 min, followed by washing with tap water to remove excess color. The plates were dried, and images were captured with a Kodak DC260 digital camera (Eastman Kodak, Rochester, NY). All experiments were performed in duplicate wells.
In vivo studies -tumor formation in nude mice All animals were used in accord with protocols approved by the animal care committees of Kyushu University. The experiment was carried out under both the Guidelines for Animal Experiments of Kyushu University and the Law (No. 105) and Notification (No. 6) of the Japanese government. Tumor suppressive effect in vivo was analyzed as described previously. 8 Briefly, H157 cells (5 Â 10 6 ) were injected s.c. into the dorsal skin of nude mice, and tumor growth was monitored for 25 days. Tumor volume was calculated according to the formula a 2 Â b, where a and b are the smallest and largest diameters, respectively, as described previously. When tumor formation was seen 10 days after inoculation, 1 Â 10 8 PFU of each virus was injected into the tumor directly. One-way analysis of variance (ANOVA) was used to compare tumor volumes, with Po0.05 being considered significant.
Results
VEGF mRNA and protein expression in various cell lines
We wished to develop a strategy for the therapy of NSCLC based on the use of a CRAd in which the VEGF promoter controls the expression of E1 (Figure 1 ). In vitro, we first investigated a panel of 12 NSCLC cell lines, one bronchial epithelial cell line (BEAS-2B) as a normal cell control, one ovarian cancer cell line (SKOV3.ipl), one gastric cancer cell line (MKN28), and a pancreatic cancer cell line (Panc-I) for VEGF expression using a RT-PCR method as reported previously. 4 There are four structural variants of VEGF (VEGF121, VEGF165, VEGF189 and VEGF206) resulting from alternative mRNA splicing in the regions encoding the cytoplasmic domains. Figure 2a shows amplification of a 408 bp fragment (representing VEGF121 cDNA) and a 541 bp fragment (representing VEGF165 cDNA) in all cell lines tested. The PCR bands corresponding to VEGF189 (615 bp) and VEGF206 (666 bp) were minimal or not detected, indicating VEGF121 and VEGF165 were dominant isoforms in these cell lines. The result is consistent with that of the previous similar analysis with primary lung cancer tissue. 4 In all cells tested, H157, A427, N417, H358 and SKOV3.ipl showed relatively high expression of VEGF mRNA, while the BEAS-2B cells showed a less intense band than the cancer cell lines, although the band corresponding to VEGF121 was detected at very low levels. Furthermore, we investigated the correlation between mRNA expression and protein expression for VEGF. As shown in Figure 2b , the VEGF protein expression levels also varied in all cell lines. H157 secreted the highest concentration of VEGF protein into the culture media, and the concentration is over 100 times higher than that of BEAS-2B. Comparison between Figure 2a and b revealed that VEGF mRNA expression level correlated with VEGF protein expression level positively. Thus, these results suggested that we could predict the VEGF promoter activity from the VEGF protein concentration.
Transgene expression by VEGF promoter in the Ad context in vitro Putative tumor-specific promoters may lose their specificity when placed in the Ad genome. Thus, in the next step we assessed the VEGF promoter activity in an Ad vector (Ad5VEGFluc) containing the luciferase gene as a reporter in several cell lines, which spanned the range of VEGF levels we detected in Figure 2 . In all of the lines tested, luciferase expression was achieved using the positive control Ad5CMVLuc, which contained luciferase gene driven by the non-selective CMV promoter. From the data with Ad5CMVLuc, A247 and H157 cells were most susceptible to Ad5 infection, which is over 100 times higher than that of H460 as shown in upper panel of Figure 3 . These data were consistent with our previous report. 8 To standardize the different susceptibility to Ad5 infection, VEGF promoter activity in each cell line was showed as the percentage of luciferase activity with Ad5VEGFLuc to Ad5CMVLuc. As shown in lower panel in Figure 3 , H157 cells showed the strongest VEGF promoter activity, 28% of CMV promoter. While BEAS-2B cells presented the lowest VEGF promoter activity, less than 0.1% of CMV. The low transgene expression by the VEGF promoter in the adenoviral context with BEAS-2B was consistent with the results reported recently. 27 Other cell lines showed various VEGF promoter activities, which correlate roughly to mRNA expression level of each cell line (cf Figure 2a) . Based on these data, we concluded that the VEGF promoter was able to induce transgene expression in VEGF producing cells and importantly that the promoter retained its specificity when placed in the Ad genome.
Transgene expression by VEGF promoter in the Ad context in vivo A key limitation of the adenovirus-mediated cancer gene therapy is the potential for toxicity to non-target organs. Because Ad has particular tropism for the liver, we were especially interested to determine whether the VEGF promoter would have low activity in the liver in vivo because the normal liver expresses minimal VEGF. Thus, Ad5VEGFLuc or Ad5CMVLuc (as a positive control) was injected i.v. via the tail vein into mice, and then the level of transgene expression at day 2 was determined ( Figure 4) . In this assay, transgene expression induced by the VEGF promoter was a mean 270-fold less than that seen with the CMV promoter in the liver. These results thus indicate the key property of VEGF promoter fidelity in the context of the Ad vector used in vivo. Additionally, we investigated the VEGF promoter activation in the tumor in vivo. As shown in Figure 4 , the tumor injected by Ad5VEGFLuc showed the 20% of that of Ad5-CMVLuc. These studies confirmed the functionality of the VEGF promoter in VEGF-positive cells in vivo as well as in vitro.
VEGF promoter driving CRAd shows replication specificity To exploit the cell specificity of the VEGF promoter in a CRAd context, we then constructed a recombinant Ad (Ad5VEGFE1) in which the native E1 promoter is replaced with the 2.6 kb human VEGF promoter. The genomic structures of replication-competent Ads used in this study are depicted in Figure 1 . In addition to using the VEGF promoter to regulate E1 expression, we used an Ad in which E1 expression is controlled by the nonselective CMV (Ad5CMVE1) promoter as a control. 16 These viruses are deleted in the E3 region and the E1A promoter region. The deleted E1A promoter region, containing native E1A TATA box, was replaced with either the VEGF promoter or CMV enhancer/promoter to produce the viruses Ad5VEGFE1 or Ad5CMVE1, respectively.
To determine the specificity of propagation of the AdVEGFE1, we infected the high VEGF expressing cell line (H157) and low expressing cell line (BEAS-2B), then used quantitative real-time PCR to determine the level of amplification of viral DNA. The non-replicative Ad5-CMVLuc and wild-type Ad5 virus (Ad5wt) were used as negative and positive controls, respectively. Since the all viruses tested here contain the Ad E4 region, viral DNA was quantified as E4 copy number by real-time PCR. As 8 6.7 11.2 2.4 4.1 6.1 4.3 8.8 9.3 10.0 3.6 8.3 1.0 shown in upper panel in Figure 5 , the Ad5VEGFE1 viral genome replicated in the high VEGF producing cancer cells, H157 to a similar extent as did the Ad5CMVE1 genome. The nonreplicative Ad5CMVLuc showed a background level of E4 signal indicating no replication in this cell line. Importantly, the replication ability of Ad5VEGFE1 decreased in the low VEGF expressing BEAS-2B cells, with values seen being is almost 3-logs lower than for Ad5CMVE1 ( Figure 5, lower panel) . These results indicate that theVEGF promoter retains fidelity even in the replication-competent adenoviral context.
Specific cell killing efficacy of VEGF promoter driving CRAd
We next investigated the ability of Ad5VEGFE1 to achieve cell killing in the VEGF-positive cell lines using an MTS assay. The viability of the high VEGF H157 cells and the low VEGF BEAS-2B cells was quantified every 3 days after virus infection as shown in Figure 6a . For the H157 cells, Ad5VEGFE1 showed a strong cytotoxic effect as did the Ad5CMVE1, positive control virus. All cancer cells died at day 9 with infection at a low MOI of 0.1 although the MTS data did not go down to zero, the lack of any remaining viable cells was confirmed using a trypan blue exclusion test. The relatively steep fall in the survival curve after day 5 suggested that it took this long before sufficient replication occurred to begin to induce toxicity. To put these results in some context with another gene-based approach to cancer treatment, we also compared the cytotoxic effect of Ad5VEGFE1 with Ad5p53, which carries the wild-type p53 gene and has been used in clinical trials. We have previously shown that H157 cells, which have a mutated p53 gene, undergo apoptosis when infected with Ad5p53. 23 Ad5p53 infection of H157 cells at MOI 0.1 showed a weak cytotoxic effect compared with Ad5VEGFE1. Similar results were obtained with A427 cells (data not shown). In contrast to the effect in the cancer cells, BEAS-2B cells were resistant to Ad5VEGFE1 toxicity even with infection at a high MOI of 10. These data were consistent with the crystal violet staining appearance as shown in Figure 5b . The cytotoxic effect of Ad5VEGFE1 to several other cancer cell lines was also evaluated in same manner with MTS assays. The data revealed that Ad5VEGFE1 had a significant cytotoxic effect to all cancer cells tested (see Discussion below).
Tumor growth suppression by Ad5VEGFE1 in vivo
We next investigated whether Ad5VEGFE1 could suppress tumor growth in vivo. To this end, we established subcutaneous tumors in nude mice, then directly injected either Ad5CMVLuc, Ad5VEGFE1 or Ad5p53 into the tumor. Tumors become visible and injectable in size 10 days after subcutaneous inoculation. Our previous work revealed that the inoculated H157 cells completed angiogenesis at this time, and form the tumor with tumor stroma, resembling actual human tumors. 8 1 Â 10 8 PFU of each virus was injected into the tumor directly, and each tumor was observed for 2 weeks. As shown in Figure 7 , the tumor injected with Ad5CMVLuc increased in size exponentially even after virus injection. Ad5p53 suppressed the tumor growth partially, but the suppressive effect was minimal. However, Ad5VEGFE1 suppressed the tumor growth significantly, but not completely at day 25 compared with Ad5p53. These findings suggested the CRAd may be a more efficacious agent than a non-replicative virus like Ad5p53 in vivo. Multiple intratumoral injection of Ad5VEGFE1 suppressed the tumor growth more strongly than single injection, and the tumor disappeared after five time injections every 5 days (data not shown).
Improvement of CRAd effect by fiber modification
The oncolytic effect of any CRAd is dependant on infectivity of the cancer cells as well as promoter activation intensity. The improvement of the Ad infectivity may lead directly to the enhancement of anticancer effect by the CRAd. 28 In this study, we found Ad infectivity for H460 lung cancer cells and SKOV3.ipl ovarian cancer cells was almost 2 logs lower than H157 and A427 lung cancer cells (Figure 3) , which may contribute to lower CRAd effect in these cell lines. We have previously reported that infectivity of serotype 5 Figure 5 Assessment of viral DNA replication 24 h after infection. 1 Â 10 5 cells were infected with replication-competent Ads (Ad5-VEGFE1, Ad5CMVE1 or Ad5wt) or nonreplicative Ad (Ad5VEGFLuc) at an MOI of 10 for 3 h and then cultured for 24 h. Viral DNA was isolated from the cells and analyzed by real-time PCR analysis to evaluate Adenoviral E4 copy number as described in Materials and methods. E4 copy numbers were normalized by the b-actin DNA copy number. Mean þ s.e. of triplicate determination is shown.
VEGF promoter-based replicative adenovirus K Takayama et al adenovirus can be improved by fiber modifications. For example, a modified Ad with a chimeric fiber which express Ad3 knob instead of Ad5 knob, Ad5/3 showed enhanced infectivity to several kinds of cancer cells. [28] [29] [30] Therefore, we analyzed the effect of infectivity enhancement with Ad5/3 for the cell lines tested in this study. As shown in Figure 8 , the luciferase activities with Ad5/3 vector increased in all six cell lines tested. The increase rates are between 5.1 times in Panc I cells and 39.4 times in A549 cells. These findings led us to make a Ad5/ 3VEGFE1 in which the Ad5 knob is replaced with Ad3 knob. Ad5/3VEGFE1 was generated and propagated as described in Materials and methods. The oncolytic effect of Ad5/3VEGFE1 for the various cancer cells was evaluated using infection at an MOI 1 to highlight the difference from Ad5VEGFE1. Cytopathic effect with Ad5/3VEGFE1 infection was seen rapidly, almost 2 days earlier than with Ad5VEGFE1 in all cell lines. In this experiment, at day 9 after infection, complete cell death was seen for all lines infected with Ad5/3VEGFE1 while a significant number of cells survived with Ad5VEGFE1 infection. Moreover, Ad5/3VEGFE1 showed a stronger cell killing effect for H322 cells and SKOV3.ipl cells compared with Ad5CMVE1. These results suggested that 
Discussion
CRAds, which show tumor specific replication and oncolysis, are promising new therapies for malignancies resistant to conventional treatments. In the current report, we demonstrate a strategy based on the use of a replication-competent Ad controlled by a VEGF promoter. Furthermore, we demonstrated the use of Ad-VFEGFE1 applicable for the treatment of a wide spectrum of tumors. With regard to gene therapy of lung cancer, replication-incompetent Ad expressing wild-type p53 is already used in clinical trials. Whereas replicationincompetent viral vectors have demonstrated great promise as anticancer agents in preclinical studies, this has not been translated into patient benefit in the clinical setting. 31 The poor anticancer effect with replicationincompetent Ad is partly depending on the weak penetration of the vector into the tumor mass. In this regard, a CRAd may achieve better intratumoral spread and penetration due to its replication ability. 32 For clinical application, prevention of hepatic toxicity is also an important consideration. Tumor cells infected with replication-competent Ad may release new viruses in vivo. If this were to occur, there would be a potential for in vivo toxicity, especially in the liver, because this is the predominant site of Ad vector localization after systemic injection. 33 In this regard, the VEGF promoter shows a low level of the promoter activity in the liver, and may avoid the hepatic injury. Since AdVEGFE1 showed good specificity in both replication rate and cytotoxicity for high versus low VEGF expressing cells, it can be expected to be less toxic to the liver compared with AdCMVE1 or wild-type Ad. Moreover, neurons express VEGF as a survival factor and cognitive damage might be expected if virus spreads to central nervous system. Unfortunately, at this time, no suitable animal models exist for the assessment of CRAd toxicity in vivo. To resolve this problem, we will investigate the CRAd toxicity using normal human hepatic cell culture in the next work. On the other hand, the results of a phase I clinical trial with VEGF inhibitors showed that these agents were well tolerated, 34 indicating a marginal role for VEGF signalling in normal organs under physiological conditions except the ovary during the menstrual cycle. 35 Another problem for the clinical use of a type II CRAd is that the relevant promoter activity in each tumor should be evaluated before treatment. From previous reports as well as our results, it is clear that tumors with low promoter activity are resistant to type II CRAds containing that promoter.
14-17 Therefore, it is important to evaluate the promoter activity in advance to avoid potentially fruitless therapy. Analysis for RNA status needs some volume of live tissue obtained from the patient to prepare RNA samples for RT-PCR or Northern blotting. Precise evaluation of promoter activity with reporter gene like luciferase is more difficult in the clinical setting generally. In this regard, the VEGF promoter has an advantage for its activity evaluation. As shown in Figures 2 and 3 , we revealed that there is a positive correlation between mRNA expression level, protein expression level and transgene activation for VEGF promoter, which is consistent with the previous report using clinical samples. 36 Taken together, these data suggest that VEGF promoter activity can be predicted from VEGF protein expression levels. VEGF protein is easily detectable in clinical samples by ELISA evaluation of fluid samples 37 and immunohistochemical staining of VEGF promoter-based replicative adenovirus K Takayama et al tissue samples. 6 Thus, these tests could potentially be used to prospectively select the most appropriate patients for consideration of VEGF-CRAd therapy in the clinical setting.
VEGF production is an important mechanism for the development of tumor-associated angiogenesis in many types of tumors. In fact, many types of cancer are already known to express the VEGF protein at significant levels, and this VEGF expression is associated with poor prognosis in several disease contexts including leukemia, breast cancer, colorectal cancer, hepatocellular carcinoma, ovarian cancer and NSCLC. 34 It seems that more advanced stage tumors actually express higher levels of VEGF protein. VEGF gene expression is known to be regulated transcriptionally. Although several transcription factors bind to the cis-elements on the promoter, hypoxia inducible factor (HIF) is the key factor to activate the promoter. 21 Hypoxia induces the transcripitional activation of the VEGF gene via HIF. The central region of tumors are often hypoxic and necrotic due to decreased blood flow, and immunohistochemical analysis of primary tumor samples shows that VEGF protein expression is enhanced in the tumor tissue adjacent to the necrotic region. 38 On the other hand, some kinds of cancer are known to express the HIF protein constitutively despite the oxygen tension, leading an increase VEGF promoter activation. 39 Taken together these findings suggest that the antitumor effect of AdVEGFE1 may be even more efficacious in large in vivo tumors than under the normoxic conditions under which our in vitro experiments were performed.
Broadly speaking, the cell killing effect of a type II CRAd may be improved by several mechanisms such as promoter induction, infectivity enhancement or an armed CRAd strategy. 40 A major obstacle to be overcome in Ad5-based cancer gene therapy has been the paucity of the primary receptor, CAR, on human primary tumor cells. Variable expression of CAR has been documented Ratio of OD490 to control Figure 9 Enhancement of cell killing effect with Ad5/3 chimeric CRAd. Cell killing effect was evaluated by MTS assay. 5 Â 10 3 cells of each cell line were infected with Ad5CMVLuc (negative control), Ad5CMVE1 (positive control), Ad5VEGFE1 or Ad5/3VEGFE1 at MOI of 1.0. After infection, cell viability in each well was quantified using OD490 by MTS assay every 3 days. The viability of cells infected with Ad5CMVE1, Ad5VEGFE1 or Ad5/3VEGFE1 was expressed as a percentage of cells infected with Ad5CMVLuc (100%).
in many cancer types. 29, [41] [42] [43] Furthermore, downregulation of CAR may be associated with a more malignant phenotype. 44 Due to variable expression of CAR on human primary cancer cells, the utility of Ad5 as a cancer gene therapy vector is compromised, limiting overall efficiency of cancer gene therapy including the use of CRAds. On this basis, systems to circumvent intervening tumor-associated CAR deficiency are required. In this regard, native Ad5 tropism can be modified to circumvent CAR deficiency and to enhance Ad infectivity. One approach is pseudotyping, that is, retargeting Ad by creating chimeric fibers possessing knob domains derived from alternate serotypes that bind to receptors other than CAR. To this end, we have constructed nonreplicating Ads containing chimeric fibers with the tail and shaft domains of Ad serotype 5 and the knob domain of serotype 3. 22 Our previous work has revealed that a distinct Ad3 receptor exists in ovarian cancer cells based on a novel knob binding assay, and that the Ad5/3 chimeric vector is retargeted to the Ad3 receptor. 29 Based on these findings, we constructed a CRAd based on the Ad5/3 chimeric approach in this study. As we hypothesized, Ad5/3VEGFE1 showed a stronger cell killing effect than that of the Ad5-based CRAd, probably due to infectivity enhancement. Thus, a chimeric vector-based CRAd is a promising way to improve the therapeutic effect. Recent data also show that Ad5/3VEGFE1 is effective to ovarian cancer in vivo. 45 In conclusion, we believe that the data presented here provide a basis for the additional development of replication-competent adenovirus strategies based on the VEGF promoter for the therapy of various cancers. Furthermore, a CRAd based on the Ad5/3 chimeric vector is promising way to enhance the anticancer effect via infectivity improvement for cancer cells.
Abbreviations NSCLC, non-small cell lung cancer; IL-8, interleukin-8; VEGF, vascular endothelial growth factor; CAR, coxsackie and adenovirus receptor; Ad5, serotype 5 adenovirus; Ad3, serotype 3 adenovirus; Ad5/3, Ad5 containing a chimeric fiber protein possessing the Ad3 knob; CRAd, conditionally replicative adenovirus; E1, early region 1; E4, early region 4; RT-PCR, revers transcription-PCR; CMV, cytomegalovirus; CsCl, cesium chloride; VP, viral particle; PFU, plaque forming unit.
